Tech Tidbits From Around NH
Kuster seeks relief for small broadband providers … and more
U.S. Rep. Annie Kuster, D-2nd Dist., is among a bipartisan group of senators and congresspersons who sent a letter urging Senate Majority Leader Mitch McConnell, Speaker of the House Nancy Pelosi, Senate Minority Leader Chuck Schumer and House Minority Leader Kevin McCarthy to include dedicated funding to help small broadband providers sustain internet services and upgrades for students and low-income families in any future legislation in response to the coronavirus pandemic.
“Many small broadband providers have committed to continue providing voice and broadband services and upgrades despite ongoing economic hardships facing many Americans,” the members of Congress wrote. “Small providers … may be unable to sustain services if customers are unable to pay for a prolonged period of time, jeopardizing broadband connectivity for customers all across this country.”
The letter urges the congressional leaders to
include in the next Covid-19 relief act “a temporary emergency relief fund at the Federal Communications Commission to help small broadband providers continue these critical services for students and low-income families throughout the pandemic.”
Jörgen Remmelg has been named CEO of XMReality Inc., a Portsmouth-based developer of augmented reality remote guidance systems. Remmelg previously was senior vice president at European high-tech company Ruag. Before that that, he served in roles at Compraser, Saab and ABB, among others.
Vapotherm Inc., an Exeter-based medical technology company focused on products that are used to treat patients suffering from respiratory distress, has been granted Breakthrough Device Designation for the company’s Oxygen Assist Module (OAM) by the U.S. Food and Drug Administration.
FDA’s Breakthrough Device Program is intended to help patients and healthcare providers receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The program creates an expedited pathway for prioritized FDA review of the OAM. Separately, Vapotherm submitted an Investigational Device Exemption (IDE) for pediatric use of OAM to FDA.